Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer

BACKGROUND: The mammalian target of rapamycin inhibitor everolimus is approved as an antitumor agent in advanced estrogen receptor-positive breast cancer. Surrogate bone marker data from clinical trials suggest effects on bone metabolism, but the mode of action of everolimus in bone biology remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Browne, Andrew J., Kubasch, Marie L., Göbel, Andy, Hadji, Peyman, Chen, David, Rauner, Martina, Stölzel, Friedrich, Hofbauer, Lorenz C., Rachner, Tilman D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551016/
https://www.ncbi.nlm.nih.gov/pubmed/28793923
http://dx.doi.org/10.1186/s13058-017-0885-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551016/
https://www.ncbi.nlm.nih.gov/pubmed/28793923
http://dx.doi.org/10.1186/s13058-017-0885-7

Ejemplares similares